Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma

2017 ◽  
Vol 40 (6) ◽  
pp. 364-369 ◽  
Author(s):  
Manlio Mencoboni ◽  
Rosa A. Filiberti ◽  
Paola Taveggia ◽  
Federica Grosso ◽  
Giulia Pasello ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Clinical Features ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma

scholarly journals Clinical Features in Patients With Malignant Pleural Mesothelioma With 5-Year Survival and Evaluation of Original Diagnoses

2020 ◽  
Vol 21 (6) ◽  
pp. e633-e639
Author(s):  
Juuso Paajanen ◽  
Sanna Laaksonen ◽  
Ilkka Ilonen ◽  
Tapio Vehmas ◽  
Mikko I. Mäyränpää ◽  
...  
Keyword(s):  
Clinical Features ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma

Clinical Features and Epidemiology of Malignant Pleural Mesothelioma in West Glasgow 1987–1992

1997 ◽  
Vol 42 (2) ◽  
pp. 37-39 ◽  
Author(s):  
A.N. McLean ◽  
K.R. Patel
Keyword(s):  
Clinical Features ◽  
Malignant Pleural Mesothelioma ◽  
Asbestos Exposure ◽  
Epidemiological Studies ◽  
Definitive Treatment ◽  
Pleural Mesothelioma ◽  
Survival Times ◽  
Building Trade ◽  
The West ◽  
Yearly Incidence

Malignant pleural mesothelioma is almost exclusively caused by exposure to asbestos dust. Recent epidemiological studies have suggested that the national incidence of disease may continue to rise until 2020 and that asbestos exposure in the building trade may be replacing shipyard related exposure as the main source of disease. The objective of the study was to determine if the incidence of malignant pleural mesothelioma was rising in the west of Glasgow from 1987–1992 and whether there had been a change in clinical features compared to previous studies from the same population. Case notes identified from coded returns and the local cancer registry were retrospectively examined: 144 cases were identified. This is an increase in incidence of over 50% compared to the previous study but the yearly incidence did not rise over the period studied. The clinical features and survival times have not changed since previous studies: median survival remains 30 weeks. Only three patients were given definitive treatment reflecting the lack of effective therapy. We suggest that the incidence of mesothelioma in the population studied may already have peaked resulting from the decline in the local shipyard industry over 20 years ago. Non-shipyard sources of asbestos exposure may be less important in this area.

Association Between Clinicopathological Factors and Genomic Abnormalities Detected by FISH Analysis in Epithelioid Diffuse Malignant Pleural Mesothelioma

2017 ◽  
Vol 25 (8) ◽  
pp. 668-673
Author(s):  
Maiko Takeda ◽  
Takahiko Kasai ◽  
Kinta Hatakeyama ◽  
Tokiko Nakai ◽  
Hiroe Itami ◽  
...  
Keyword(s):  
Clinical Features ◽  
Malignant Pleural Mesothelioma ◽  
Clinical Stage ◽  
Fish Analysis ◽  
Pleural Mesothelioma ◽  
Clinicopathological Factors ◽  
Fish Method ◽  
Diffuse Malignant Pleural Mesothelioma ◽  
Worse Prognosis

Background. Abnormality of genes including 9p21 is known in malignant mesothelioma and we have examined the frequency of gene deletion and amplification using the fluorescence in situ hybridization (FISH) method. We formerly reported that abnormality of the genes was more common in the sarcomatoid type than epithelioid type. In this study, we compared the clinicopathological factors including nuclear grade (NG) and genomic abnormality in epithelioid malignant pleural mesothelioma (MPM). Methods. Using paraffin-embedded tissues of 31 epithelioid MPMs, we investigated the presence of gene abnormalities in the genes 9p21, 1p36, 14q32, 22q12, 5p15, 6p, 8q24, and 7p12 by the FISH method, and compared the results with NG, clinical stage, and prognosis. Results. In the higher NG group of epithelioid MPM, more gene amplifications [in particular 5p15 and 8q24(MYC)] were observed, and clinical stage was more advanced. Cases with the amplification of 7p12(EGFR) tended to exhibit a worse prognosis. The significant correlation between histological differentiation and clinical features such as prognosis was not confirmed. Conclusions. NG status in epithelioid MPM may be related to gene alteration and clinical features.

scholarly journals Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma

2014 ◽  
Vol 48 (2) ◽  
pp. 163-172 ◽  
Author(s):  
Katja Goricar ◽  
Viljem Kovac ◽  
Vita Dolzan
Keyword(s):  
Treatment Outcome ◽  
Treatment Response ◽  
Malignant Pleural Mesothelioma ◽  
Cox Regression ◽  
Liver Toxicity ◽  
Progression Free Survival ◽  
Pleural Mesothelioma ◽  
Folate Pathway ◽  
Lower Response Rate ◽  
Great Heterogeneity

Abstract Introduction. A combination of pemetrexed and cisplatin has been shown to improve the outcome in patients with malignant pleural mesothelioma (MPM), however, there is a great heterogeneity in treatment response among patients. The aim of our study was to evaluate the influence of polymorphisms in folate pathway and transporter genes on pemetrexed treatment outcome in Slovenian patients with MPM. Methods. MPM patients treated with pemetrexed in the course of a prospective randomized clinical trial were genotyped for nineteen polymorphisms in five genes of folate pathway and six transporter genes. Logistic regression was used to assess the influence of polymorphisms on treatment efficacy and toxicity, while Cox regression was used to determine their influence on progression-free and overall survival. Results. Patients with at least one polymorphic MTHFD1 rs2236225 allele had a significantly lower response rate (p = 0.005; odds ratio [OR] = 0.12; 95% confidence interval [CI] = 0.03−0.54) and shorter progression-free survival (p = 0.032; hazard ratio [HR] = 3.10; 95% CI = 1.10−8.74) than non-carriers. Polymorphisms in transporter genes did not influence survival; however, several were associated with toxicity. Liver toxicity was significantly lower in carriers of polymorphic ABCC2 rs2273697 (p = 0.028; OR = 0.23; 95% CI = 0.06−0.85), SLCO1B1 rs4149056 (p = 0.028; OR = 0.23; 95% CI = 0.06−0.85) and rs11045879 (p = 0.014; OR = 0.18; 95% CI = 0.05−0.71) alleles compared to non-carriers, as well as in patients with SLCO1B1 GCAC haplotype (p = 0.048; OR = 0.17; 95% CI = 0.03−0.98). Gastrointestinal toxicity was much more common in patients with polymorphic ABCC2 rs717620 allele (p = 0.004; OR = 10.67; 95% CI = 2.15−52.85) and ABCC2 CAG haplotype (p = 0.006; OR = 5.67; 95% CI = 1.64−19.66). Conclusions. MTHFD1 polymorphism affected treatment response and survival, while polymorphisms in ABCC2 and SLCO1B1 transporter genes influenced the risk for toxicity. These polymorphisms could serve as potential markers of pemetrexed treatment outcome in patients with MPM.

scholarly journals P1.06-05 Clinical Features and Outcomes of Recurrence After Pleurectomy/Decortication for Malignant Pleural Mesothelioma

2019 ◽  
Vol 14 (10) ◽  
pp. S478-S479
Author(s):  
A. Nakamura ◽  
M. Hashimoto ◽  
A. Kuroda ◽  
T. Nakamichi ◽  
S. Matsumoto ◽  
...  
Keyword(s):  
Clinical Features ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma

scholarly journals Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma

2015 ◽  
Vol 76 (2) ◽  
pp. 319-328 ◽  
Author(s):  
Assunta De Rienzo ◽  
Michael A. Archer ◽  
Beow Y. Yeap ◽  
Nhien Dao ◽  
Daniele Sciaranghella ◽  
...  
Keyword(s):  
Clinical Features ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma ◽  
Gender Specific
Sign in / Sign up

Export Citation Format

Share Document